Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

IMO, the breakthrough designation for '113 is especially good for patients in the UK.

As I recall, the UK's NIH turned down crizotinib as a covered medication because it did not meet the minimum quality-adjusted life-year benefit measure. (IIRC, this is about $30k/QALY.)

At the time, I noted that this left the UK as a wide-open market segment, albeit of a small-ish indication.

We'll see whether that still turns out to be the case, given that '113 has gotten a boost in what has unfortunately become a bit of a race to the market for 2nd-gen ALK drugs.